Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Docetaxel vs Docetaxel + Radium-223 in mCRPC
2018-002944-10Phase 3Active
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Docetaxel with Docetaxel + Radium-223 (2 arms). Primary endpoint: Overall survival. Started Nov 2018; status: active.
02
Drugs
docetaxelradium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2018-002944-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002944-10.